PRODUCTS   METHODS
 
 
 

Luciferase Reporter Stable Cell Lines

 
Product   Principle   Data   Literature   Price/Order   Message
 

 

Gene function analysis, target discovery and validation, assay development, and compound screening often need cell-based assays.  Stable cell lines that are engineered to express a gene of interest via transgene integrations into the host genome provide an efficient approach to conduct such analysis.  At Signosis, we help researchers save time and labor in generating and validating stable cell lines so scientists can spend more effort on solving the big questions.  We offer a wide-selection of validated luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways.

 

Benefits:
  • Routine mycoplasma testing - All cell lines tested negative for mycoplasma.
  • High sensitive and responsive - Each cell line is validated to induce strong reporter signal in response to stimuli.
  • Consistent - TF reporter construct is stably integrated into the genome to avoid experimental/cell-to-cell variations.
  • Time saving - Cell line can be used for experiments right away to study different signaling pathways.
  • Firefly Luciferase Substrate -  Click to learn more about Signosis luciferase substrate.

 

Transcription Factors Pathway Cell Line
Academic  Industry
  • NFkB
NFkB Hela; human cervical cancer SL-0001-NP SL-0001-FP
NFkB NFkB NIH/3T3; mouse fibroblast SL-0006-NP SL-0006-FP
NFkB NFkB HEK293; human embryonic kidney SL-0012-NP SL-0012-FP
NFkB  NFkB MCF-7; human breast cancer SL-0013-NP SL-0013-FP
NFkB NFkB A549; human lung cancer SL-0014-NP SL-0014-FP
NFkB NFkB HepG2; human liver cancer SL-0017-NP SL-0017-FP
NFkB NFkB Neuro2a; mouse neuroblastoma SL-0026-NP SL-0026-FP
NFkB NFKB MDA-MB-231, Human brest cancer SL-0043-NP SL-0043-FP
NFkB NFkB MEF; murine embryonic fibroblast
SL-0033-NP SL-0033-FP
NFKB NFKB Jurkat T; Human T Lymphocyte SL-0050-NP SL-0050-FP
NFAT   Calcium Signaling Jurkat T; human T lymphocyte
SL-0032-NP SL-0032-FP
  • NFAT
Calcium Signaling Hela; human cervical cancer SL-0018-NP SL-0018-FP
  • NFAT
Calcium Signaling NIH/3T3; mouse fibroblast SL-0029-NP SL-0029-FP    
  • p53
p53 Hela; human cervical cancer SL-0011-NP SL-0011-FP
p53 p53 RKO; human colon cancer SL-0007-NP SL-0007-FP
  • SMAD 2/3
TGFbeta pathway
HepG2; human liver cancer SL-0016-NP SL-0016-FP
  • SMAD 2/3
TGFbeta pathway
NIH/3T3; mouse fibroblast SL-0030-NP SL-0030-FP
  • SMAD 1/5/8
BMP pathway HEK293; human embyronic kidney SL-0051-NP SL-0051-FP
  • NRF2/ARE
Antioxidant Response HEK293;Human embyronic kidney
SL-0042-NP   SL-0042-FP
  • NRF2/ARE
Antioxidant Response NIH3T3;Mouse fibroblast
SL-0047-NP   SL-0047-FP
  • NRF2/ARE
Antioxidant response HepG2; Human Liver cancer SL-0046-NP     SL-0046-FP
  • NRF2/ARE
Antioxidant Response MCF7; human breast cancer SL-0010-NP academic only
  • STAT1
JAK-STAT Hela; human cervical cancer SL-0004-NP SL-0004-FP
  • STAT3
JAK-STAT Hela; human cervical cancer SL-0003-NP SL-0003-FP
  • HIF
Hypoxia Response NIH/3T3; mouse fibroblast SL-0005-NP SL-0005-FP
HIF Hypoxia Response Hela; human cervical cancer SL-0023-NP SL-0023-FP
HIF Hypoxia Response Neuro2a; mouse neuroblastoma SL-0027-NP SL-0027-FP
  • HIF
Hypoxia Response Cos-7; Monkey  fibroblast SL-0034-NP SL-0034-FP
  • ER
Estrogen Receptor Signaling T47D; human breast cancer SL-0002-NP SL-0002-FP
  • AR
Androgen Receptor Signaling MDA-MB-453; human breast cancer SL-0008-NP SL-0008-FP
  • GR
Glucocorticoid Receptor Signaling MDA-MB-453; human breast cancer SL-0009-NP SL-0009-FP
GR Glucocorticoid Receptor Signaling Hela; human cervical cancer SL-0021-NP SL-0021-FP
  • AP-1
JNK, ERK, MAPK Signaling Hela; human cervical cancer SL-0019-NP SL-0019-FP
  • CREB
cAMP, PKA, CaMK Signaling HEK293; human embryonic kidney SL-0020-NP SL-0020-FP
  • CREB
cAMP, PKA, CaMK Signaling NIH/3T3; mouse fibroblast SL-0031-NP SL-0031-FP
  • CHOP
Unfolded Protein Response, ER stress Mia-Paca2; human pancreatic cancer SL-0025-NP SL-0025-FP
  • TCF/LEF
Wnt/b-catenin HEK293; human embryonic kidney SL-0015-NP SL-0015-FP
TCF/LEF Wnt/b-catenin Hela; human cervical cancer SL-0022-NP SL-0022-FP
  • TCF/LEF
Wnt/b-catenin CHO-K1;Chinese Hamster Ovary
SL-0028-NP SL-0028-FP    
ELK MAPK Signaling HEK293; human embyronic kidney
SL-0040-NP SL-0040-FP
  • ELK
MAPK Signaling
Hela; human cervical cancer
SL-0041-NP SL-0041-FP    
IRF Immune Response Pathway
HEK293; human embyronic kidney
SL-0035-NP SL-0035-FP
IRF Immune Response Pathway HePG2;Human Liver Cancer SL-0049-NP SL-0049-FP
ATF6 Unfolded Protein Response, ER stress CHO-K1;Chinese Hamster Ovary SL-0024-NP SL-0024-FP
IL-6 MAPKs, PI3Ks, STATs Signaling
HEK293; human embryonic kidney SL-0048-NP SL-0048-FP
IFN-α/ISRE TYK2 and JAK1 Signaling
HeLa; human cervical cancer
SL-0052-NP SL-0052-FP
MRF Metal Pathway HEK293; human embryonic Kidney
SL-0053-NP SL-0053-FP
FXR Liver, Inflammatory responses HepG2; human liver cancer SL-0055-NP SL-0055-FP
Control   Hela; human cervical cancer SL-0038  
Control    HepG2; human liver cancer SL-0039  
         

 


 

IFN-a/ISRE Luciferase Reporter HeLa Stable Cell Line


Interferon-alpha (IFN-α) binds to receptor subunits IFNαR1 and IFNαR2 on the cell surface, which initiate the phosphorylation of TYK2 and JAK1 and trigger downstream cascade of JAK-Stat signal transduction pathways. IFN-α can also induce the formation of Interferon-stimulated gene factor 3 (ISGF3), composed of STAT1, STAT2, and IRF9. The ISGF3 complexes bind ISRE (IFN-stimulated response elements) further inducing the transcription of IFN-stimulated genes which contain ISREs within their promoters that leads to transcription of selected genes. Signosis developed the IFN-α/ISRE luciferase reporter stable cell line to monitor IFN-α associated JAK-Stat pathway.

Cell Lines Available Available:

IFN-α/ISRE Luciferase Reporter HeLa Stable Cell Line (Non-Profit) SL-0052-NP
IFN-α/ISRE Luciferase Reporter Hela Stable Cell Line (Profit) SL-0052-FP



NRF2/ARE Luciferase Reporter HEK293 Stable Cell Line


NRF2/ARE plays a crucial role in cellular anti-oxidant defense, making it a therapeutic target for neurodegenerative diseases and cancer.  Under normal conditions, NRF2/ARE localizes in the cytosol and is rapidly degraded by the proteasome.  Under oxidative stress, NRF2/ARE is stabilized and translocates to the nucleus where it binds to a DNA promoter and initiates gene expression.  In the nucleus, NRF2/ARE forms a heterodimer with a small Maf protein and binds to the Antioxidant Response Element in the upstream promoter region of many antioxidative genes, and initiates their transcription.

 

This NRF2/ARE luciferase reporter stable cell line has been stably transfected with pTA-ARE-luciferase reporter vector, which contains 4 repeats of antioxidant response binding sites, a minimal promoter upstream of the firefly luciferase coding region, along with a hygromycin expression vector.  Following selection, the hygromycin resistant clones were subsequently screened for TBHQ-induced luciferase activity. The clone with the highest fold induction was selected and expanded to produce this stable cell line.




FXR Luciferase Reporter HepG2 Stable Cell Line (Non-profit)


Farnesoid X receptor (FXR, NR1H4) is a member of the nuclear hormone receptor superfamily. These nuclear hormone receptors are ligand-activated transcription factors that elicit their actions by binding to hormone response elements (HREs) in the promoters of target genes and regulating transcription in response to lipophilic ligands.
Similar to other nuclear receptors, when activated, FXR translocates to the cell nucleus, forms a dimer with RXR and binds to hormone response elements on DNA, which up- or down-regulates the expression of certain genes, involved in lipid and glucose homeostasis which play a crucial role in pathophysiology of many major diseases such as diabetes, obesity, atherosclerosis and heart failure. In addition, FXR activation has been shown to be critical in the regulation of inflammatory responses.
Signosis now offers FXR-Luciferase reporter stable cell line to the research community. This high-quality stable cell lines will facilitate further molecular studies of FXR pathway its functions.




FXR Luciferase Reporter HepG2 Stable Cell Line (For-profit)


Farnesoid X receptor (FXR, NR1H4) is a member of the nuclear hormone receptor superfamily. These nuclear hormone receptors are ligand-activated transcription factors that elicit their actions by binding to hormone response elements (HREs) in the promoters of target genes and regulating transcription in response to lipophilic ligands.
Similar to other nuclear receptors, when activated, FXR translocates to the cell nucleus, forms a dimer with RXR and binds to hormone response elements on DNA, which up- or down-regulates the expression of certain genes, involved in lipid and glucose homeostasis which play a crucial role in pathophysiology of many major diseases such as diabetes, obesity, atherosclerosis and heart failure. In addition, FXR activation has been shown to be critical in the regulation of inflammatory responses.
Signosis now offers FXR-Luciferase reporter stable cell line to the research community. This high-quality stable cell lines will facilitate further molecular studies of FXR pathway its functions.




HIF Luciferase Reporter Cos-7 Stable Cell Line


Hypoxia-Inducible Factor (HIF)-1 is a dimeric protein complex that plays a central role in the response to low oxygen concentrations, or hypoxia, and  is a crucial physiological regulator of homeostasis, vascularization, and anaerobic metabolism. HIF is a transcription factor regulating gene expression by binding to their DNA recognition site on the target genes. Furthermore, HIF-1 has been widely studied because of its perceived therapeutic potential.  HIF-1 allows survival and proliferation of cancerous cells due to its angiogenic properties, and the inhibition potentially could prevent the spread of cancer. With a growing understanding of the HIF-1 pathway, it has become an attractive goal to analyze the inhibition and stimulation of HIF transcriptional activity via small molecules. Signosis has established a HIF luciferase reporter stable cell line that has been stably transfected with pTA-HIF-luciferase reporter vector, which contains 4 repeats of HIF binding sites, a minimal promoter upstream of the firefly luciferase coding region. This cell line can be used to monitor the activation of HIF in response to the different stimuli, such as CoCl2 or deferroxamine.




HIF Luciferase Reporter Cos-7 Stable Cell Line


Hypoxia-Inducible Factor (HIF)-1 is a dimeric protein complex that plays a central role in the response to low oxygen concentrations, or hypoxia, and  is a crucial physiological regulator of homeostasis, vascularization, and anaerobic metabolism. HIF is a transcription factor regulating gene expression by binding to their DNA recognition site on the target genes. Furthermore, HIF-1 has been widely studied because of its perceived therapeutic potential.  HIF-1 allows survival and proliferation of cancerous cells due to its angiogenic properties, and the inhibition potentially could prevent the spread of cancer. With a growing understanding of the HIF-1 pathway, it has become an attractive goal to analyze the inhibition and stimulation of HIF transcriptional activity via small molecules. Signosis has established a HIF luciferase reporter stable cell line that has been stably transfected with pTA-HIF-luciferase reporter vector, which contains 4 repeats of HIF binding sites, a minimal promoter upstream of the firefly luciferase coding region. This cell line can be used to monitor the activation of HIF in response to the different stimuli, such as CoCl2 or deferroxamine.




NFkB Luciferase Reporter MDA-MB-231 Stable Cell Line


NFkB plays an important role in controlling many biological processes including immune and inflammatory responses, developmental processes, cellular growth, and apoptosis. In response to the various stimuli, such as stress, cytokines, free radicals, ultraviolet irradiation, and bacterial or viral antigens, NFkB is activated and translocates from cytoplasm to nucleus, where NFkB binds to its response element on the promoter region and regulates a wide spectrum of gene expression. Dysfunction of NFkB activity is associated with cancer, inflammatory and autoimmune disease, and viral infection. Monitoring the NFkB activity is essential to unveil the mechanism of these diseases and conduct drug discovery. Signosis has established an NFkB luciferase reporter stable cell line that has been stably transfected with pTA-NFkB-luciferase reporter vector, which contains 4 repeats of NFkB binding sites, a minimal promoter upstream of the firefly luciferase coding region. Therefore, the cell line can be used as a reporter system for monitoring the activation of NFkB triggered by stimuli treatment, enforced gene expression and gene knockdown.  

The stable cell line can be used for studying NFkB signaling pathways activated by different cytokines, such as TNFa, IL-1a and IL-1b, and many other stimuli.




IL-6 Responsive Luciferas Reporters HEK293 Cell Line (Non-Profit)


Interleukin-6 (IL-6) is a multifunctional cytokine which plays an important role in a wide range of biologic processes in different types of cell including cancer cells. IL6 can stimulate multiple pathways involving MAPKs, PI3Ks, STATs, and other signaling proteins, and subsequently activate its downstream targets in the regulation of cell proliferation, survival, and metabolism. Even though IL6 was originally characterized as a regulator of immune and inflammatory responses, elevated expression and activities of IL-6 has been detected in multiple cancers, such as breast, lung and lymphoma.  IL-6 was associated with tumor progression through increasing antiapoptotic activity, stimulation of angiogenesis, and drug resistance. The increased serum IL-6 concentrations in patients are linked to the advanced tumor stages of various cancers and short survival rate. Developing drugs to block pathological IL-6 overproduction has become a potential therapeutic strategy for cancers.

Cell Lines Available Available:

IL-6 Responsive Luciferase Reporter HEK293 Stable Cell Line (Non-Profit) SL-0048-NP
IL-6 Responsive  Luciferase Reporter HEK 293 Stable Cell Line (Profit) SL-0048-FP



IL-6 Responsive Luciferas Reporters HEK293 Cell Line


Interleukin-6 (IL-6) is a multifunctional cytokine which plays an important role in a wide range of biologic processes in different types of cell including cancer cells. IL6 can stimulate multiple pathways involving MAPKs, PI3Ks, STATs, and other signaling proteins, and subsequently activate its downstream targets in the regulation of cell proliferation, survival, and metabolism. Even though IL6 was originally characterized as a regulator of immune and inflammatory responses, elevated expression and activities of IL-6 has been detected in multiple cancers, such as breast, lung and lymphoma.  IL-6 was associated with tumor progression through increasing antiapoptotic activity, stimulation of angiogenesis, and drug resistance. The increased serum IL-6 concentrations in patients are linked to the advanced tumor stages of various cancers and short survival rate. Developing drugs to block pathological IL-6 overproduction has become a potential therapeutic strategy for cancers.

Cell Lines Available Available:

IL-6 Responsive Luciferase Reporter HEK293 Stable Cell Line (Non-Profit) SL-0048-NP
IL-6 Responsive  Luciferase Reporter HEK 293 Stable Cell Line (Profit) SL-0048-FP



IRF Luciferase Reporter HEPG2 Cell Line


Members of the interferon regulatory transcription factor (IRF) family are involved in antiviral defense, cell growth regulation, and immune activation.  Initially identified as regulators of type I interferon (IFN) gene induction, IRF family of transcription factors transduce signals for multiple classes of the pattern-recognition receptors (PRRs), such as Toll-like receptors, retinoic acid–inducible gene-I (RIG-I)-like receptors (RLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs), and other nucleic acid–sensing receptors.  When activated, each IRF protein translocates to the nucleus and binds to DNA sequence similar to IFN-stimulated response element (ISRE).  IRF activation can enhance the IFN-mediated antiviral immune response.  Oppositely, abnormal activation of type I IFNs contributes to the development of autoimmune diseases, such as SLE.  Signosis has established an IRF luciferase reporter stable cell line that can be used as a reporter system for monitoring the activation of IRF triggered by stimuli treatment, enforced gene expression and gene knockdown.


The cell line is established by transfection using a pTA-GAS/ISRE-luciferase reporter vector, which contains IRF binding sites, a minimal promoter upstream of the firefly luciferase coding region, along with hygromycin expression vector followed by hygromycin selection.  The hygromycin resistant clones were subsequently screened for IFNgamma-induced luciferase activity.

Cell Lines Available: (Click for pricing and catalogue numbers)

IRF Luciferase Reporter HEPG2 Stable Cell Line (Non-Profit) SL-0049-NP
IRF Luciferase Reporter HEPG2 Stable Cell Line (For-Profit) SL-0049-FP



IRF Luciferase Reporter HEPG2 Cell Line ( for Profit)


Members of the interferon regulatory transcription factor (IRF) family are involved in antiviral defense, cell growth regulation, and immune activation.  Initially identified as regulators of type I interferon (IFN) gene induction, IRF family of transcription factors transduce signals for multiple classes of the pattern-recognition receptors (PRRs), such as Toll-like receptors, retinoic acid–inducible gene-I (RIG-I)-like receptors (RLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs), and other nucleic acid–sensing receptors.  When activated, each IRF protein translocates to the nucleus and binds to DNA sequence similar to IFN-stimulated response element (ISRE).  IRF activation can enhance the IFN-mediated antiviral immune response.  Oppositely, abnormal activation of type I IFNs contributes to the development of autoimmune diseases, such as SLE.  Signosis has established an IRF luciferase reporter stable cell line that can be used as a reporter system for monitoring the activation of IRF triggered by stimuli treatment, enforced gene expression and gene knockdown.


The cell line is established by transfection using a pTA-GAS/ISRE-luciferase reporter vector, which contains IRF binding sites, a minimal promoter upstream of the firefly luciferase coding region, along with hygromycin expression vector followed by hygromycin selection.  The hygromycin resistant clones were subsequently screened for IFNgamma-induced luciferase activity.

 

Cell Lines Available: (Click for pricing and catalogue numbers)

IRF Luciferase Reporter HEPG2 Stable Cell Line (Non-Profit) SL-0049-NP
IRF Luciferase Reporter HEPG2 Stable Cell Line (For-Profit) SL-0049-FP



BMP Responsive Luciferase Reporter HEK293 Cell Line (For-Profit)


Bone morphogenic protein (BMP) is involved in embryogenesis, development of many organ systems and adult tissue homeostasis. Smads (Smad1/5/8) are activated during the signal transduction and then form a complex with Smad4, translocate into the nucleus where they regulate expression of transcriptional factors and transcriptional coactivators
Deficiency in BMP production or functionality usually leads to marked defects or severe human diseases associated with most organ systems. Monitoring the BMP activity is essential to research of the BMP signaling-associated diseases and conduct drug discovery.
Signosis has established a BMP luciferase reporter stable cell line that has been stably transfected with pTA-BMP-luciferase reporter vector, which contains 4 repeats of BMP binding sites, a minimal promoter upstream of the firefly luciferase coding region. Therefore, the cell line can be used as a reporter system for monitoring the activation of BMP triggered by stimuli treatment, enforced gene expression and gene knockdown.

Cell Lines Available: (Click for pricing and catalogue numbers)

BMP Responsive Luciferase Reporter HEK293 Cell Line (Non-Profit) SL-0051-NP
BMP Responsive Luciferase Reporter HEK293 Cell Line (For-Profit) SL-0051-FP



BMP Luciferase Reporter HEK293 Cell Line (Non-Profit)


Bone morphogenic protein (BMP) is involved in embryogenesis, development of many organ systems and adult tissue homeostasis. Smads (Smad1/5/8) are activated during the signal transduction and then form a complex with Smad4, translocate into the nucleus where they regulate expression of transcriptional factors and transcriptional coactivators
Deficiency in BMP production or functionality usually leads to marked defects or severe human diseases associated with most organ systems.  Monitoring the BMP activity is essential to research of the BMP signaling-associated diseases and conduct drug discovery.
Signosis has established a BMP luciferase reporter stable cell line that has been stably transfected with pTA-BMP-luciferase reporter vector, which contains 4 repeats of BMP binding sites, a minimal promoter upstream of the firefly luciferase coding region. Therefore, the cell line can be used as a reporter system for monitoring the activation of BMP triggered by stimuli treatment, enforced gene expression and gene knockdown.

Cell Lines Available: (Click for pricing and catalogue numbers)

BMP Responsive Luciferase Reporter HEK293 Cell Line (Non-Profit) SL-0051-NP
BMP Responsive Luciferase Reporter HEK293 Cell Line (For-Profit) SL-0051-FP